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Abstract
The transporter associated with antigen processing (TAP) and the major histocompatibility complex class I (MHC-I), two
important components of the MHC-I antigen presentation pathway, are often deficient in tumor cells. The restoration of
their expression has been shown to restore the antigenicity and immunogenicity of tumor cells. However, it is unclear
whether TAP and MHC-I expression in tumor cells can affect the induction phase of the T cell response. To address this issue,
we expressed viral antigens in tumors that are either deficient or proficient in TAP and MHC-I expression. The relative
efficiency of direct immunization or immunization through cross-presentation in promoting adaptive T cell responses was
compared. The results demonstrated that stimulation of animals with TAP and MHC-I proficient tumor cells generated
antigen specific T cells with greater killing activities than those of TAP and MHC-I deficient tumor cells. This discrepancy was
traced to differences in the ability of dendritic cells (DCs) to access and sample different antigen reservoirs in TAP and MHC-I
proficient versus deficient cells and thereby stimulate adaptive immune responses through the process of cross-
presentation. In addition, our data suggest that the increased activity of T cells is caused by the enhanced DC uptake and
utilization of MHC-I/peptide complexes from the proficient cells as an additional source of processed antigen. Furthermore,
we demonstrate that immune-escape and metastasis are promoted in the absence of this DC ‘arming’ mechanism.
Physiologically, this novel form of DC antigen sampling resembles trogocytosis, and acts to enhance T cell priming and
increase the efficacy of adaptive immune responses against tumors and infectious pathogens.
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Introduction
Adaptive T cell immune responses play a critical role in
controlling and destroying tumor cells. However, tumors that are
deficient in components of the MHC-I antigen presentation
pathway, such as TAP and MHC-I, are often observed to escape T
cell responses [1–5]. This is due to failure in presentation of tumor
antigens on the cell surface when TAP and MHC-I are absent [2–
5]. TAP functions to transport cytosolic-generated peptides into
the lumen of the endoplasmic reticulum (ER) for MHC-I binding,
followed by transport of MHC-I/peptide complexes to the cell
surface for T cell recognition.
Restoration of TAP and MHC-I expression in tumor cells has
been demonstrated to increase T cell-based tumor antigen-specific
immune responses [6–11]. Such responses consist of two phases,
the induction and effector phases. The induction phase occurs in
the early stages of the T cell immunity, initiating tumor-antigen
recognition and antigen specific T cell generation and prolifera-
tion, while the effector phase occurs in later stages of the immune
response, affecting T cell activation, recognition and destruction of
antigen-expressing tumor cells. Using existing antigen specific T
cells, many reports have confirmed that increased TAP and
MHC-I expression in tumor cells restores the capacity for antigen
presentation and thus enhances recognition and destruction of
tumor cells by antigen specific T cells [10,12–14]. These reports
provide evidence that TAP and MHC-I expression facilitates T
cell immunity in the effector phase. In addition to these, there are
several studies indicating that restoration of TAP and MHC-I
expression in tumor cells can augment T cell-based anti-tumor
immune responses in both the induction and effector phases, by
augmenting tumor immunogenicity. In these studies, tumor
immunogenicity augmented by TAP and/or MHC-I expression
was measured using tumor-cell-induced T cell responses to
monitor the capacity for antigen processing and presentation of
the tumor [10,14] or through the use of tumor-bearing mice as a
model to determine the length of survival as a quotient for
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not distinguish between the induction versus the effector phases of
an adaptive immune response, it is still uncertain if enhanced
tumor immunogenicity is due to an increase in activity of tumor
antigen-specific T cells during the induction phase of the T cell
response.
Induction of anti-viral and anti-tumor T cell-based immunity
requires professional antigen presenting cells, such as bone-
marrow derived DCs (BM-DCs) [15–18]. DCs acquire antigen
proteins from apoptotic or necrotic tumor cells and process and
present them via the MHC-I antigen presentation pathway to the
surface for T cell priming. This processing pathway is termed
cross-presentation and is an important mechanism for T cell
generation [16,19]. A study on allorecognition has provided
additional evidence for the effectiveness of cross-presentation by
showing that DCs were capable of acquiring substantial levels of
allogeneic MHC-I from donor cells [20]. In this process, DCs
appear to capture MHC-I and likely present antigens directly to T
cells. The physiological relevance of this mechanism in vivo has
not been established and it is unclear whether such a mechanism is
suitable for the induction of anti-viral or anti-tumor T cell
responses in addition to conventional DC cross-presentation.
In the present study, we examined different forms of a model
antigen VSV-Np derived from the vesicular stomatitis virus
nucleocapsid protein to address the induction phase of the T cell
response and determined whether tumor cells that have reconsti-
tuted TAP and MHC-I expression can prime antigen specific T
cells with increased killing via DC-sampling of surface MHC-I/
peptide complexes.
Results
TAP and MHC-I expression in tumors increases tumor-
antigen specific immunity both in vitro and in vivo
To evaluate TAP and MHC-I function in the induction phase
of the T cell response, we transfected TAP1, TAP2 and/or K
b
genes into TAP and MHC-I deficient CMT.64 cells. All
transfectants expressed the relevant gene(s) (Fig. 1A and 1B). K
b
expression in CMT.64 cells was not detected by a conformational
dependent AF6-88.5 mAb but was visible using Y-3 mAb, and the
level of expression in the cells was lower than the level shown in
CMT.1,2/K
b cells. CMT.TAP1/pEF4 cells expressed a level of
K
b lower than CMT.TAP1/K
b (Fig. 1A). All gene-transfectants
expressed mouse TAP1 while only CMT.TAP1,2/K
b expressed
TAP2 (Fig. 1B). The empty vector-transfectant CMT.64/ppp had
K
b and TAP expression levels similar to CMT.64 (data not
shown). Functional assays indicated that presentation of a K
b-
restricted epitope VSV-Np52–59 derived from VSV-Np protein
varied among these transfectants (Fig. 2A). Since this epitope can
be transported onto the surface of TAP-proficient and TAP1-
expressing cells but not TAP-negative cells [2], our results
indicated that presentation of this epitope correlated with levels
of K
b molecules as well as with TAP expression.
Next, we performed in vitro and in vivo experiments to determine
whether the TAP and MHC-I proficient CMT.TAP1,2/K
b was
able to induce tumor-antigen specific immunity. For in vitro
experiments, c-irradiated CMT.64 and CMT.TAP1,2/K
b were
used to immunize mice and the two immunized splenocyte
populations were compared for tumor-antigen recognition using a
51Cr-release assay. CMT.64-generated splenocytes recognized
CMT.TAP1,2/K
b at low levels similar to CMT.64 (figure 2B
left-panel), while the CMT.TAP1,2/K
b-generated splenocytes
killed CMT.TAP1,2/K
b with higher efficiency than CMT.64
(Fig. 2B right-panel). This was also observed in an in vivo challenge
experiment. The CMT.TAP1,2/K
b-immunized mice challenged
with live CMT.TAP1,2/K
b had a longer survival rate than the
CMT.64/ppp-immunized mice (P,0.05, Figure 2C). Although
survival of the CMT.64/ppp-immunized group tended to be
longer than the negative control group (non-immunized mice),
statistical analysis showed no significance (P.0.05). In contrast to
immunocompetent mice, protection by immunization with
CMT.TAP1,2/K
b cells was not observed in a nude mouse model
that lacks antigen specific T cells (data not shown). These
experiments demonstrated that expression of surface MHC-I/
peptide complexes increased protection in tumor-bearing mice,
likely due to increased tumor-antigen specific immunity.
In spite of TAP and MHC-I expression increasing tumor-
antigen specific immunity, the importance of the induction phase
of this response was still not addressed because clonal selection in
response to the CMT.TAP1,2/K
b and the CMT.64/ppp cells
may be dependent on factors other than TAP and K
b expression.
For example, different levels of antigen protein expression may
have influenced induction of the immune response. To resolve this
question and determine if TAP and K
b expression can potentiate
the induction of tumor-antigen specific immunity, a model antigen
was introduced into the tumor cells to induce production of
antigen-specific T cells and to determine T cell activities.
Efficient killing activity of antigen-specific CTLs
generated by c-irradiated TAP and K
b expressing cells
infected with VV carrying mini-genes
To evaluate the effects of TAP and K
b expression in tumor cells
on enhancement of T cell priming, we performed a
51Cr-release
assaytodetermineantigen-specificT cellactivity.VV-VSV-Np52–59
-infected CMT.TAP1,2/K
b and CMT.64 were inoculated i.p. into
naı ¨ve mice and the immunized splenocytes were used as a source of
T cells. Since the VV carried a VSV-Np52–59 minigene, the viral
infected cells generated only the peptide epitope but not the entire
VSV-Np protein. It is important to note that, while both cell lines
expressed equivalent amounts of viral antigen, the CMT.TAP1,
2/K
b cells could present VSV-Np52–59 peptide on their cell surface
whereas the CMT.64 cells could not (Fig. 2A). As shown in Fig. 3A,
the CMT.TAP1,2/K
b-generated CTLs had killing activity higher
than the CMT.64-generated CTLs.
We subsequently compared cytolytic activities of two T cell
populations generated by immunization of VV-VSV-Np52–59-
infected CMT.TAP1/pEF4 or CMT.TAP1/K
b cells. These two
cell lines expressed TAP1 only and therefore the transport of the
VSV-Np52–59 peptide into the lumen of the ER and subsequent
expression of MHC I/peptide complexes at the cell surface may be
reduced in comparison with TAP1 and 2 expressing cells (see
Fig. 2A). In this setting the capacity for T cell priming between
these two cell lines differs in the levels of MHC I and MHC-I/
peptide complexes displayed at the cell surface. With higher K
b
expression,theCMT.TAP1/K
bcellspresentedmoreVSV-Np52–59
peptide on the cell surface than the CMT.TAP1/pEF4 cells when
both cell lines were infected with VV-VSV-Np52–59, as demonstrat-
ed by CTL killing (Fig. 2A). The CMT.TAP1/K
b-generated
splenocytesexhibited a higher killing activity than the CMT.TAP1/
pEF4-generated splenocytes (Fig. 3B). Furthermore, we designed an
additional experiment to address this issue through direct infection
ofCMT.64 and CMT.TAP1,2/K
b cellswitha VV-ss-VSV-Np52–59
virus. Peptide epitopes governed by an ER-signal sequence (ss) can
bypass the requirement of TAP function to be transported into the
ER lumen where the peptides are cleaved to remove the signal
sequence for MHC-I binding [21–23]. In this experimental system,
synthesized peptideepitopescanfreely enterthe ERlumen and thus
the key component for antigen presentation appears to be the
T Cell Priming by TAP & MHC-I
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b molecules within the secretory compartment. In
this experiment, the immunization of mice with VV-ss-VSV-
Np52–59-infected CMT.TAP1,2/K
b cells generated a CTL popu-
lation with killing activity higher than those immunized with the
viral infected CMT.64 cells (Figure 3C left panel). The viral
infection slightly increased the surface K
b expression in both
CMT.64 and CMT.1,2/K
b cells (Fig. 3 C right panel). Thus, these
results suggest that MHC-I expression contributes to the greater
efficiency of T cell priming of K
b-expressing CMT.64 transfectants.
To confirm that the VV-VSV-Np52–59 viruses themselves did
not prime antigen specific T cell generation, we compared the
abilities of the irradiated and non-irradiated VV-VSV-Np52–59
viruses to induce VSV-Np52–59 epitope specific T cells. Two
splenocyte populations generated from the mice inoculated with c-
irradiated and non-irradiated VV-VSV-Np52–59 were compared
with respect to their killing activities. CTLs generated by live, but
not irradiated VV-VSV-Np52–59 showed killing activity (Fig. 3D).
These results indicate that irradiation abrogated CTL generation.
Low dose dependency of VV-VSV-Np-infected
CMT.TAP1,2/K
b cells in priming a VSV-Np52–59-specific
CTL population
To test the effect of TAP and K
b on T cell priming by antigens
from the entire VSV-Np protein, we infected CMT.TAP1,2/K
b
and CMT.64 cells with 1:20 pfu VV-VSV-Np that contained the
Figure 1. Expression of transfected TAP and K
b molecules in CMT.64 cells. K
b and TAP expression in CMT.64 transfectants was examined. A)
FACS assay was performed to detect expression of the K
b molecule by direct immunostaining using R-PE-conjugated K
b-specific mAb AF6-88.5, and
R-PE-conjugated K
k-specific Ab 36-7-5 was used as a control (top panel). In addition, indirect immunostaining was performed using Y-3 Ab against K
b
followed by labeling with FITC-conjugated goat anti-mouse IgG Ab. The samples labeled with only FITC-conjugated goat anti-mouse IgG Ab were
used as controls (meddle panel). B) Western blots were performed to detect mouse TAP1 and TAP2 expression using the respective polyclonal
antibodies respectively (see Material and Methods). GAPDH protein was detected in each sample as the loading control.
doi:10.1371/journal.pone.0003097.g001
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from the immunized mice were tested. Unexpectedly, killing
activities of the two CTL populations were equally potent (data
not shown), suggesting that the MHC-I/peptide complexes did not
participate in T cell priming under these experimental conditions.
One possible explanation for this observation is that cells infected
with VV-VSV-Np at 1:20 (m.o.i) generated amounts of the VSV-
Np protein sufficient for T cell priming, thereby obscuring the
effects of surface antigen-loaded K
b complex on the induction of T
cells. In order to understand this phenomenon, the
CMT.TAP1,2/K
b and CMT.64 cells were infected at a reduced
m.o.i of the VV-VSV-Np, and VSV-Np protein expression and T
cell activities of the viral infected cell-generated CTLs were
examined by Western blot and
51Cr-release assay respectively
(Fig. 4). At a dose of 1:20 (m.o.i) infection, both cell lines expressed
a large but equal amount of the VSV-Np protein, which decreased
with reduced doses of viral infection. However, at the minimum of
1:0.05 (m.o.i), VSV-Np protein was still detectable (Fig. 4A). When
assayed for CTL activity, the CTL population generated by viral
infected CMT.TAP1,2/K
b cells at the lowest dose showed a killing
activity significantly greater than the CTL population generated at
the equivalent m.o.i using viral-infected CMT.64 cells (Fig. 4B).
However, the increased activities were not observed in CTL
populations generated by the viral infected CMT.TAP1,2/K
b cells
Figure 2. CMT.64 TAP/MHC I transfectants but not wild-type CMT.64 cells present antigens and induce an immune response. In vitro
cytotoxicity assays and in vivo challenge assays were performed to determine the antigen presentation by the tumor cells and anti-tumor immune
response. A) Determination of antigen presentation: Cells were infected with VV-VSV-Np52-59 at 1:20 (m.o.i) overnight, labeled with
51Cr and used as
the targets. The VSV-Np52–59 specific splenocyte-derived CTLs were generated by immunization of mice with VV-VSV-Np52–59 at 2610
7 (pfu) viruses
per mouse. The target to effector ratio used was 1:100. a – CMT.64; b – CMT.TAP1/pEF4; c – CMT.TAP1/K
b and d – CMT.TAP1,2/K
b. The mean value of
the results from two experiments is shown. B) Determination of anti-tumor immune response: CMT.64 and CMT.TAP1,2/K
b immunized splenocytes
were used as two effectors and
51Cr-labeled CMT.64 and CMT.TAP1,2/K
b cells were used as targets. The mean value of the results from two
experiments is shown. C) Left: Mice were immunized ip. with 1610
7 c-irradiated CMT.TAP1,2/K
b, CMT.64/ppp cells (experimental control) or PBS
(negative control. After day 20 of immunization, the mouse was challenged ip. with 2.5610
5 cells/mouse CMT.TAP1,2/K
b cells. Each group contained
10 mice. Time of morbidity was recorded. Statistical analysis of survival curves is shown below: P.0.05 was used for comparison between CMT.64/
ppp-immunized and negative control groups; P,0.001 was for the comparison between CMT.TAP1,2/K
b-immunized and negative control; P,0.05
was used for comparison between the CMT.TAP1,2/K
b- and CMT.64/ppp-immunized groups. It should be noted that CMT.64/ppp, instead of CMT.64,
were used to immunize mice is to control for immune responses against components of the three vectors used to transfect TAP and K
b.
doi:10.1371/journal.pone.0003097.g002
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b expressing tumor cells. Standard 4-h
51Cr-
release assays were performed to detect the killing activities of the spleen-derived antigen specific CTLs. The CTLs were generated by immunization
of 1610
7 cells/mouse c-irradiated CMT.64, CMT.TAP1/pEF4, CMT.TAP1/K
b or CMT.TAP1,2/K
b cells that were infected with VV-VSV-Np52–59 B or VV-ss-
VSV-Np52–59 virus at 1:20 (m.o.i) overnight and re-stimulated with VSV-Np52–59 peptide in vitro. The
51Cr-labeled 39.5/K
b cells pulsed with or without
VSV-Np52–59 peptide were used as targets. A) Square symbol — CTLs generated by CMT.64+VV-VSV- Np52–59; Round symbol — CTLs generated by
CMT.TAP1/K
b+VV-VSV-Np52–59. The mean value of the results from three experiments is shown. B) Square symbol — CTLs generated by CMT.TAP1/
pEF4+VV-VSV-Np52–59; Round symbol — CTLs generated by CMT.TAP1/K
b+VV-VSV-Np52–59. The mean value of the results from three experiments is
T Cell Priming by TAP & MHC-I
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1) low but not high protein antigen expression primed a T cell
population with increased killing activity in CMT.TAP1,2/K
b
cells; and 2) T cell cytolytic activities were decreased when antigen
protein expression was increased.
Frequency of antigen specific T cells is not increased in
animals immunized with viral infected CMT.TAP1/K
b and
CMT.TAP1,2/K
b cells
To determine if the number of antigen specific T cells influences
their killing activities, a K
b/VSV-Np52–59 tetramer assay was
performed in two pairs of splenocyte-populations from immunized
mice to quantify the percentage of antigen specific CD8
+ cytolytic
T cells. VV-VSV-Np52–59 infected CMT.64 and CMT.TAP1,2/
K
b generated splenocyte-populations were compared and viral
infected CMT.TAP1/pEF4 and CMT.TAP1/K
b generated
splenocyte-populations were used in another comparison. All
immunized splenocytes were stimulated in vitro with VSV-Np52–59
peptide for 5 days and then each was divided into two aliquots;
one was used as effectors in cytotoxicity assays as shown in Fig. 3A
and B and another was used to quantifyVSV-Np52–59 specific and
K
b–restricted T cells in the tetramer assay (Fig. 5). Results showed
that neither the percentages of tetramer positive cells in total
splenocytes nor the total CD8
+ T cells were increased in the
CMT.TAP1,2/K
b-generated population, compared with the
CMT.64-generated population (Fig. 5, Exp. I). In addition, similar
results were observed in the CMT.TAP1/K
b-generated and
CMT.TAP1/pEF4-generated populations (Fig. 5, Exp. II). These
results together with the results shown in Fig. 3A and B suggest
that TAP and K
b-expressing cells generated T cell populations
with different effector potency instead of increasing the number of
antigen-specific T cells.
Uptake of surface MHC-I/peptide complex from the
tumor cells by BM-DCs
Since the observed increase in T cell response was based on
priming by c-irradiated cells, it was possible that DCs play an
important role in antigen uptake from the apoptotic cells for T cell
shown. C) Left: Square symbol — CTLs generated by CMT.64+VV-ss-VSV-Np52–59; Round symbol — CTLs generated by CMT.TAP1,2/K
b+VV-ss-VSV-
Np52–59. The results represented the mean value from three experiments. Right: FACS assay was performed to detect surface K
b expression. D). CTLs
were generated by immunization of mice with 1610
7 pfu c-irradiated (Left panel) and non-irradiated (Right panel) VV-VSV-Np52–59. The results
represent the mean value from two experiments.
doi:10.1371/journal.pone.0003097.g003
Figure 4. Increased killing activity of CTLs generated by CMT.TAP1,2/K
b infected with the lowest dose of VV-VSV-Np. The
CMT.TAP1,2/K
b and CMT.64 cells were infected with VV-VSV-Np virus at varied m.o.i. A) Western blots were performed to detect VSV-Np protein
expression. B) Standard 4-h
51Cr-release assays were conducted to determine the activities of the CTLs generated by varied viral-dose infected
CMT.TAP1,2/K
b and CMT.64 cells (1610
7 cells/mouse). The
51Cr-labeled 39.5/K
b cells pulsed with VSV-Np52–59 peptide were used as targets. 1:50
target to effector ratio is shown. The mean value of the results from two experiments is shown.
doi:10.1371/journal.pone.0003097.g004
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remains as to why, if equal amounts of antigen expression in
CMT.64 and CMT.TAP1,2/K
b (by viral infection) were taken up
by DCs, do differences in cross-priming explain the differences in
T cell responses. To answer this, we focused on examining the
surface MHC-I/peptide complex of the tumor cells to determine if
DCs are able to utilize them as an additional source of antigen for
T cell priming.
BM-DCs were obtained from BALB/c mice (designated as B-
BM-DCs) that express H-2
d (K
d and D
d) molecules. If B-BM-DCs
incubated with c-irradiated CMT.TAP1,2/K
b infected with VV-
VSV-Np52–59 could be recognized by the VSV-Np52–59 specific T
Figure 5. Similar frequencies of VSV-Np52–59 specific T cells generated by immunization of different tumor cells. Tumor cells were
infectedwithVV-VSV-Np52–59 overnightandwerec-irradiated.Thecellsweretheninjectedintomice.Afterimmunization,thefrequencyofVSV-Np52–59
specific CD8
+ T cells derived from splenocytes was analyzed by FACS assay using double staining with an anti-mouse CD8a antibody and a K
b/VSV-
Np52–59specifictetramer. Thegatingareawassetuptoincludeallcellsexcept erythrocytes anddebris (right plotattoppanel). Exp.I andExp.IIindicate
that tetramer assays were performed separately. One out of two tetramer assays is shown. The numbers inserted in each picture represent the mean
value of results (mean6SEM) from two experiments. Numbers shown in top are percentages of tetramer positive cells in total CD8
+ T cells. Numbers
shown in bottom are percentages of tetramer positive cells in total splenocytes.
doi:10.1371/journal.pone.0003097.g005
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b/peptide complex from the donor
cells were sampled, acquired and expressed on the plasma
membrane of recipient DCs and this facilitated functional
recognition of the transferred MHC-I/antigen complexes. We
performed a
51Cr-release assay to detect donor K
b/peptide
complex presentation by B-BM-DCs. The CMT.64 cells were
usedasacontrol,asunliketheCMT.TAP1,2/K
b,theVSV-Np52–59
epitope is not transported onto the cell surface in association with
K
b molecules (Fig. 2A). VSV-Np52–59 CTLs killed the B-BM-DCs
incubated with CMT.TAP1,2/K
b more efficiently than those
incubated with CMT.64 (Figure 6A). In addition to monitoring
cytolytic activity, the surface MHC-I transfer event was directly
observed using a GFP-tagged-K
b-vector system. CMT.TAP1,2/K
b
and CMT.64 cells were transiently transfected with a GFP-tagged-
K
b-vector overnight and GFP expression was detected by
fluorescence microscopy and FACS assay (Fig. 6B and C). After
overnight transfection, GFP expression could be detected in
approximately 65–67% of cells; however, within these cells, the
GFP expression was weakly expressed in 51–55% of the transfected
cells. A transient GFP expression system was necessary since the
GFP vector required neomycin screening, which was already
present in our current cell lines (see Material and Methods). The
GFP-tagged-K
b-transfectants were then c-irradiated and incubated
with C57BL/6-derived BM-DCs (designated as C-BM-DCs) to
follow DC’ uptake of GFP-K
b molecules. The GFP-tagged MHC-I
uptake was determined by fluorescence microscopy and FACS
analysis. Fluorescence microscopic results (Fig. 6B bottom) revealed
little uptake of the GFP-tagged K
b by DCs from co-culture with
CMT.64 cells while intense green color was visualized in DCs co-
cultured with CMT.TAP1,2/K
b cells. These results suggested that
DCs are able to directly acquire portions of plasma membrane from
the tumor cells. FACS analysis demonstrates that the DC
population co-cultured with GFP-tagged-K
b-transfected
CMT.TAP1,2/K
b cells acquires a fluorescence intensity higher
than the DCs co-cultured with GFP-tagged-K
b-transfected
CMT.64 cells (Fig. 6C, right panel). These results indicate that
DCs can efficiently acquire and re-utilize transferred surface MHC-
I/Peptide complexes from TAP expressing tumor cells through a
trogocytosis-like process [24].
T cell priming by BM-DCs activated by acquiring H-2K
b/
VSV-Np complexes from the surface of infected cells
An important issue to consider is if the amount of MHC-I/
peptide complexes taken up by DCs, is it sufficient to induce
production of antigen specific T cells. To address this issue, both
B-BM-DCs and C-BM-DCs were injected into C57BL/6 mice to
generate T cell responses. Differences exist in the MHC-I
molecules expressed by the B-BM-DCs versus the C-BM-DCs
that can participate in T cell priming. If the donor MHC-I-loaded
B-BM-DCs can not efficiently induce T cell responses while the
MHC-I-loaded C-BM-DCs can induce efficient T cell responses,
this would explain the observation that antigens from exogenous
MHC-I/peptide complexes alone are not sufficient to induce
immune responses. To test this possibility, we performed in vivo
cytotoxicity assays for B-BM-DCs. B-BM-DCs were loaded with
either c-irradiated, VV-VSV-Np52–59-infected CMT.64 or
CMT.TAP1,2/K
b cells for ‘arming’. After washing extensively
to discard the potential donor cells, the individually armed B-BM-
DC populations were injected i.p into separate groups of C57BL/
6 mice to elicit VSV-Np antigen immunized carriers. The
experiment was repeated twice and the results from a represen-
tative experiment are depicted in (Fig. 7A). The results
demonstrate that B-BM-DCs armed and loaded with
CMT.TAP1,2/K
b-derived antigens primed an immune response
(60% killing) greater than B-BM-DCs loaded with CMT.64-
derived antigens (50% killing). These results were similar to in vitro
51Cr-release assay using C-BM-DCs as immune stimulators
(Fig. 7B). In addition to viral infected tumor samples for DC
uptake, samples from CMT.64 cells pulsed with different amounts
of VSV-Np52–59 peptide were also used to evaluate DC-uptake.
We performed a dose response of CMT.64 cells pulsed with varied
amounts of the peptide in order to examine the threshold
sensitivity of CTL recognition and killing. These experiments
provided information regarding the amounts of the K
b/VSV-Np
complexes on the cell surface that are required for recognition by
antigen specific CTL and allowed us to extrapolate the amounts of
MHC-I/peptide complexes that would be available for transfer to
DCs. Figure 7C (left panel) shows that killing of CMT.64 cells
pulsed with 0.01, 0.5 or 5 mM VSV-Np52–59 peptide were epitope-
dose dependent, suggesting that the 0.01,5 mM peptide concen-
tration range titrated and assembled different numbers of K
b
molecules with peptides on the surface of CMT.64 cells in a dose
dependent fashion. Thus, different amounts of K
b/VSV-Np
complexes were available for uptake by DCs. To determine if
different amounts of K
b/VSV-Np complexes taken up by DCs
induced T cells with different levels of killing activities, DCs co-
cultured with c-irradiated CMT.64 cells pulsed with 0.01, 0.5 or
5 mM peptide followed by extensive washing were inoculated
separately into three groups of mice. The VSV-Np epitope specific
T cells were generated by immunization of mice with c-irradiated
39.5/K
b cells pulsed with VSV-Np52–59 peptide. Results from
Figure 7C (right panel) demonstrate that the three bulk-cultures of
VSV-Np-epitope elicited specific T cells exhibited different
capacities for killing peptide-pulsed target cells and that killing
activity of T cells was dependent on the number of K
b/VSV-Np
complexes from the peptide-pulsed CMT.64 cells available for DC
uptake during T cell induction. The greater the number of
complexes generated, the more heightened the T cell killing
activity. These results suggested that the transfer of surface MHC-I
molecules from tumors or infected cells to DCs participated in
antigen specific T cell priming in vivo.
Discussion
Priming T cell generation is a key initial step in T cell-based
immune responses against tumor cells and pathogens [18,25].
Here we show that reconstituting expression of TAP and MHC-I
in c-irradiated tumor cells or in virally infected cells can prime and
increase the killing activities of antigen specific T cells and can also
increase the survival rates of tumor-bearing mice. These findings
are highly correlated with cross-presentation of the pathogen or
tumor’s MHC-I/peptide complex via acquisition, insertion and re-
expression into the plasma membrane of newly ‘armed’ BM-DCs.
Such observations may provide important information for
augmenting the induction phase of adaptive T cell immunity,
thereby increasing the efficacy of tumor and pathogen specific
immune responses.
The amount of available antigen is an important parameter for
induction of adaptive T cell responses [26]. Generally, increasing
antigen concentration will prime higher activities of antigen
specific T cells. For example, immunization of mice with high, but
not low, amounts of chicken ovalbumin protein [27] or apoptotic
tumor cells [26] will induce increased T cell generation, and the
degree of T cell activation correlates with the dose of antigen
acquired by DCs [28]. Bullock et. al also showed that DCs pulsed
with higher concentrations of immunogenic peptides enhanced the
number of activated CD8
+ T cells [29,30]. The results of our
experiments demonstrate that the increased activity of T cells is
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rather the availability of these antigens processed onto the surface
of donor tumor cells or infected cells. Expression of TAP and K
b
molecules allows both VSV-Np52–59 and the tumor antigenic
peptides to be transported through the secretory pathway for
binding to K
b molecules, thereby displaying the antigenic peptide/
Figure 6. Uptake of the MHC-I/peptide complex and expression on the surface of the tumor cells by BM-DCs. Uptake of K
b molecules
by BM-DCs was quantified using in vitro cytotoxicity assays, multi-channel fluorescence microscopy and FACS assays. A) B-BM-DCs were incubated
with c-irradiated CMT.64 or CMT.TAP1,2/K
b cells that were infected with 1:10 pfu VV-VSV-Np52–59. The matured B-BM-DCs were used as
51Cr-labeled
targets in cytotoxicity assays. The mean value of the results (Mean6SEM) from two experiments is shown. B). C-BM-DCs were co-cultured with c-
irradiated CMT.64 and CMT.TAP1,2/K
b cells transiently transfected with GFP-tagged K
b vector (green color). After 6 hours incubation, DCs were
treated with LPS overnight. DC samples were then labeled with Alexa Fluor 647 anti-mouse CD11c antibody (red color), and dual-channel
fluorescence was visualized by using a Zeiss AxioObserver Z1 widefield microscope. The top-panel indicates that tumor cells transiently expressed
GFP-tagged K
b and that most cells were weakly GFP positive. The bottom-panel (including inserted images) indicates that DCs took up the green
label from tumor cells. Arrows show the same cells enlarged. C). FACS assays was performed to detect GFP expression. Left panel: CMT.64 cells (green)
and CMT.TAP1,2/K
b cells (red) transiently transfected with GFP-tagged K
b vector overnight and GFP expression was detected. CMT.64 cells without
transfection (Blue) were used as control. CMT.TAP1,2/K
b cells without transfection has fluorescence intensity similar to CMT.64 cells (data not shown).
In inserted table, M1 shows the percentage of total GFP positive cells; M2 shows the percentage of weak GFP positive cells and M3 shows the
percentage of high GFP positive cells. Right panel: C-BM-DCs, that were prepared similar to those depicted in B, were labeled with PE-conjugated
anti-mouse CD11c. GFP-fluorescence intensity of DCs in a histogram at top was gated for CD11c positive cells (shown in a dot-plot at bottom). a —
DCs incubated with c-irradiated CMT.64 cells; b — DCs incubated with c-irradiated, GFP-tagged K
b transfected CMT.64 cells; c — DCs incubated with
c-irradiated, GFP-tagged K
b transfected CMT.TAP1,2/K
b cells.
doi:10.1371/journal.pone.0003097.g006
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b complex on the cell surface. Thus, the complexes of surface
antigenic peptide-loaded K
b molecules provide an available source
of preprocessed antigen, that upon transfer to a DC, can enhance
T cell priming.
Our results demonstrate that surface MHC-I molecules were
directly acquired and taken up by BM-DCs and inserted into their
plasma membranes for display to T cells. The phenomenon of
uptake of surface MHC-I may involve the transfer of plasma
Figure 7. T cell priming by BM-DCs activated by H-2K
b/VSV-Np complexes on the surface of tumor cells. A) B-BM-DCs were incubated
with c-irradiated CMT.64 or CMT.TAP1,2/K
b cells that were infected with 1:10 pfu VV-VSV-Np52–59. After extensive washing, B-BM-DCs were
immunized to naı ¨ve C57BL/6 mice to perform in vivo cytotoxicity assays. The C57BL/6 mice without immunization were used as controls (see material
and methods for detail). One representative of two experiments is shown. In the two experiments, the mean value (percentage) of killing was
57.5%62.5 (Mean % killing6SEM) for DCs co-cultured with c-irradiated and VV-VSV-Np52–59-infected CMT.TAP1,2/K
b and 46.5%63.5 (Mean %
killing6SEM) for DCs co-cultured with c-irradiated and VV-VSV-Np52–59-infected CMT.64. B) C-BM-DCs were treated as A) and immunized to naı ¨ve
C57BL/6 mice. Spleens from the immunized mice were used as CTLs. Standard 4-h
51Cr-release assays were performed and the 39.5/K
b cells pulsed
with or without VSV-Np52–59 were used as targets. The mean value of the results from three experiments is shown. C). Standard 4-h
51Cr-release assays
were performed. Left panel: CMT.64 cells pulsed with 0.01, 0.5 and 5 mM VSV-Np52–59 peptide were used as target cells, and CTLs were generated by
immunization with 39.5/K
b cells pulsed with VSV-Np52–59 peptide. Right panel: C-BM-DCs were incubated with c-irradiated CMT.64 cells that were
pulsed with 0.01, 0.5 or 5 mM VSV-Np52–59 peptide. After extensive washing, the DCs were injected into mice to generate VSV-Np52–59 epitope
specific CTLs (splenocytes). RMA-S and VSV-Np52–59 (2 mM) peptide-pulsed RMA-S cells were used as targets. I, II and III indicated that CTLs
generated by immunization of DCs co-cultured with CMT.64 cells pulsed with 0.01 (I), 0.5 (II) and 5 (III) mM peptide. The results represent the mean
value of the results from two experiments.
doi:10.1371/journal.pone.0003097.g007
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(bottom panel). It is still not clear why surface localization of GFP-
tagged-K
b on the DCs cannot be observed by fluorescence
microscopy while it can be detected by cytotoxicity assays (Fig. 6A),
but likely relates to relative sensitivity of the analytical procedures.
Thus, since the majority of the GFP- tagged-K
b tumor cells weekly
expressed GFP, it is possible that after DC uptake and display, the
relatively small numbers of K
b molecules/peptide complexes that
were transferred were difficult to observe with fluorescence
microscopy techniques. The cytotoxicity assay is a very sensitive
method facilitating the detection of the K
b molecules [1].
Alternatively, the process and transfer of K
b molecules onto the
DC surface may be time dependent and this has not been
optimized under our present experimental paradigm.
Different levels of MHC-I/peptide complexes produced by DCs
pulsed with CMT.64 or CMT.TAP1,2/K
b cells can yield varied
levels of antigen specific T cells. However, the killing activities of T
cell populations are dependent on the levels of MHC-I/peptide
complexes taken up by DCs for stimulation of primary T cells as
suggested by the results shown in Fig. 7C. These results provide an
explanation why immunization with MHC-I proficient
(CMT.TAP1,2/K
b) cells can increase the generation and
production of T cells resulting in immune responses greater than
those adaptive T cell responses generated by immunization with
MHC-I deficient (CMT.64) cells. It is noteworthy and surprising
that the different cytotoxic killing levels of effector T cells did not
always correlate with the frequency of antigen specific T cell
populations (Fig. 5). Such a correlation has often been observed by
others [25,31,32]. Thus, our results suggest that the MHC-I/
peptide complexes taken up and displayed by DCs can activate
and ‘tune’ the immune system in a unique or complementary
fashion to traditional forms of exogenous and endogenous antigen
processing pathways. This process acts to augment the generation
of antigen specific T cell subsets with enhanced cytolytic activity.
In the present study, results obtained from peptide-based and
protein-based VSV-Np antigens showed differences in T cell
activities. Cells infected with high doses of peptide-based antigen,
induced higher cytolytic killing activities of antigen specific T cells
as well as increased killing activity of T cells in a TAP and MHC-I
dependent manner, while this pattern was observed only in
protein-based antigens at the lowest dose. Two important
questions are raised from these results. First, why are high doses
of VSV-Np protein-based antigen incapable of priming a T cell
population with higher killing activity? Secondly, why is the
increased T cell response in TAP and MHC-I dependent T cell
response detected only at the lowest dose of VSV-Np protein-
based antigen? Since VSV-Np protein is derived from an
infectious pathogen, high levels of VSV-Np (protein-based) but
not the (peptide-based) VSV-Np mini-antigen may be directly
cytotoxic to components of the immune system. This possibility is
supported by a recent report indicating that a novel influenza virus
mitochondrial protein can kill host immune cells responding to the
influenza viral infection [33]. However, vaccinia virus-derived
proteins appear to be nontoxic to the immune system, as the
minigene-based VV virus can induce higher killing activities of
VSV-Np specific T cells at higher doses of infection. Alternatively,
there may be competition for antigen processing at higher doses of
infection between the vaccinia viral protein antigens and the VSV-
Np protein. This competition would not exist in peptide-based T
cell priming because the cells infected with the minigene-based VV
can immediately synthesize peptide epitopes for ER-lumen
transport and MHC-I binding. The answer to the second question
may be explained by DC-based cross-presentation. Antigen uptake
by DCs not only includes proteins, peptides, and molecular
chaperone-associated peptides [34–37] but also surface MHC-I/
peptide complexes [present results and [20]]. As discussed above,
the latter event explains why TAP and MHC-I expressing tumor
cells can prime a better a T cell response in peptide-based T cell
priming. Once VSV-Np52–59 peptides are synthesized in the cells,
only small amounts of the peptide that associate with K
b and
molecular chaperones [34] can escape the protease-hydrolysis
processing and prime T cell generation via the cross-presentation
pathway [35–37]. Thus, under these conditions, the high number
of surface K
b/peptide complexes becomes an important additional
antigen source for T cell priming. In contrast, in cross-presentation
of whole protein-based antigens, the large amount of VSV-Np
protein taken up by DCs provides a source of antigens that alone
may be enough for cross-presentation and T cell priming. Thus,
antigen presentation following processing of whole protein-based
antigens and the subsequent transfer of MHC-I/peptide com-
plexes to DCs may be less evident.
By using the VSV-Np model antigen, we have demonstrated
that DCs efficiently cross-present antigens from TAP and MHC-I
expressing donor tumor cells or infected cells for T cell generation.
Increased survival of mice immunized with c-irradiated MHC-I
proficient tumor (CMT.TAP1,2/K
b) cells is likely due to this
mechanism. A conflicting report exists from Huang et al [15] who
used the MHC-I negative B78H1 and its MHC-I proficient
transfectant (derived from B16 melanoma) as a model system to
immunize mice and then challenged with MHC-I positive B78H1
cells. They demonstrated that both immunized mouse groups had
similar survival rates and confirmed that the immune responses
against tumor cells were CD8 positive T cell dependent, as judged
by pre-treatment of mice with Ab against CD8 [15]. There are two
possible reasons for the discrepancy between these results and our
present study. B78H1 cells and CMT.64 cells may express
different levels or types of tumor antigens accessing different
pathways of antigen processing [38]. If B78H1 cells express high
levels of a particular tumor antigen while CMT.64 cells express
low levels, the surface MHC-I on relevant MHC-I transfectants
may play different roles in DC-based cross-priming. As suggested
by our VSV-Np protein-based experiment (Fig. 4), in donor tumor
cells expressing whole protein antigen, surface MHC-I/peptide
complexes will have a less observable effect on DC cross-
presentation. Alternatively, it is likely that B78H1 and its MHC-
I transfectant are not only sensitive to CD8 T cells but also to NK
and CD4 T cells as well [39]. This was confirmed, in a later study
by the same group where they showed that B78H1 cells lacked
TAP2 expression [40] become sensitive to NK-mediated killing.
As a result, these immune components may provide reinforcement
for the antigen specific tumor immune response and thus the effect
of surface MHC-I expression on CD8
+ T cell priming becomes
less evident.
In summary, our results demonstrate for the first time that
MHC-I/antigenic peptide complexes derived from TAP and
MHC-I expressing cells but not TAP and MHC-I deficient cells
can enhance T cell priming and subsequently increase the cytolytic
activity of antigen specific T cell populations. Operationally, this
serves to reduce mortality in tumor bearing mice. The effect of the
increased capacity for induction of T cell generation is apparently
associated with sampling the MHC-I/peptide complexes ex-
pressed on the surface of tumor and virally infected cells that is
donated to recipient DCs and then displayed at their cell surface
for priming of T cell responses. The newly identified mechanism
antigen processing, leading to T cell induction, appears to be
distinct from surrogate antigen processing and peptide secretion
described previously [41], but appears analogous to trogocytosis
[24], and possibly to cross-dressing [42]. This pathway provides
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enabling DC cross-priming. Subversion of this DC ‘arming’
mechanism appears to drive immune-escape and metastasis.
Finally, the phenomena we have discovered, likely plays a role
in provoking responses to other pathogens and perhaps in
autoimmune responses and self-tolerance mechanisms.
Materials and Methods
Animals
The C57BL/6 (H-2
b) and BALB/c (H-2
d) mouse strains were
obtained from NCI and housed in the animal facility at LSU
Health Sciences Center. All mice used for the experiments were 6–
10 wk old females and were maintained in pathogen-free facilities
and treated in accordance with the guidelines of Animal Use
Committee at LSU Health Sciences Center.
Vectors
Vaccinia virus (VV) vectors carrying an entire VSV-nucleocap-
sid gene (VV-VSV-Np), an epitope-minigene (VV-VSV-Np52–59)
orasignalsequence-linkedepitope-minigene(VV-ss-VSV-Np52–59)
were kindly provided by Dr. Yewdell [23] (Laboratory of Viral
Diseases, National Institute of Allergy and Infectious Diseases,
Bethesda, MD). Mouse TAP1 and TAP2 vectors were provided by
Dr. Wang (Institute of Cell and Molecular Science, Barts and
London School of Medicine, London, UK). Mouse TAP1 and
TAP2 cDNAs were isolated and inserted into the vectors
pcDNA3.1/His and pUB6/V5-His (Invitrogen Corporation,
Carlsbad, CA), respectively. A K
b-vector was provided by Dr.
Flavell (Section of Immunobiology, Yale University School of
Medicine, New Haven, CT) and the K
b cDNA was isolated and
inserted into the vector pEF4/Myc-His (Invitrogen). A GFP-tagged
K
b vector containing neomycin selected-marker was provided by
Dr. Edidin [42] (Department of Biology, Johns Hopkins University,
Baltimore, Maryland).
Cell lines and cell culture
The mouse lung carcinoma cell line CMT.64 was kindly
provided by Dr. Gunnel Hallden (Imperial College of Science,
London, UK). Four CMT.64 transfectants were generated by
transfection with empty vector, mouse TAP1, TAP2 and/or K
b
gene(s). CMT.TAP1/pEF4 and CMT.TAP1/K
b cell lines were
generated by co-transfection of TAP1 with either a pEF4/Myc-
His empty or a K
b vector respectively. Both were maintained in
1000 mg/ml neomycin and 60 mg/ml zeocin selection medium.
CMT.TAP1,2/K
b and CMT.64/ppp transfectants were generat-
ed by co-transfection with TAP1, TAP2 and K
b or relevant empty
vectors. Both were maintained in 1000 mg/ml neomycin, 60 mg/
ml zeocin and 20 mg/ml blasticidin selection medium. A K
b-
transfected D122 lung carcinoma cell line, 39.5/K
b [6] was
maintained in 500 mg/ml neomycin selection medium. The cell
lines were maintained in DMEM medium (Life Technologies,
Rockville, MD), while cell lines RMA and RMA-S was cultured in
RPMI 1640 medium.
H-2K
b expression
Surface H-2K
b expression was detected by a FACScan analyzer
(Becton Dickinson, Mountain View, CA) using direct and indirect
immunofluorescence. For direct labeling, a PE-conjugated mono-
clonal antibody (mAb) anti-H-2K
b AF6-88.5 and a PE-conjugated
anti-H-2K
k mAb 36-7-5 (BD Biosciences, San Jose, CA) were
used. For indirect labeling, an H-2K
b specific Y-3 primary mAb
and FITC-conjugated goat anti-mouse IgG secondary antibody
(Ab) were used.
Detection of TAP and VSV-Np expression
Expression of mouse TAP1 and TAP2 proteins were deter-
mined by Western blots [14]. For TAP1 expression, blots were
incubated in a goat anti-mouse TAP1 polyclonal Ab with 1:1000
dilution (according to instructions of manufacturer) followed by an
HRP-labeled bovine anti-goat Ab (1:2000 dilution) (both from
Santa Cruz Biotechnology, Santa Cruz, CA). For TAP2
expression, blots were incubated in mouse antiserum with
1:1000 dilution followed by an HRP-labeled goat anti-mouse
IgG Ab (1:3000 dilution) (Santa Cruz Biotechnology). Mouse
antiserum against mouse TAP2 protein was created for this study
by immunizing BALB/c mice with a peptide sequence (mapping
at the C-terminus of mTAP2), DGQDVYAHLVQQRLEA-C
with a cysteine at the C-terminus, linked to a keyhole limpet
hemocyanin (KLH) carrier protein (Pierce Biotechnology, Rock-
ford, IL). This antiserum can detect mouse TAP2 protein in lysates
of RMA but not in TAP2 deficient RMA-S and CMT.64 cells. For
VSV-Np detection, a rabbit serum (gift from Dr. Luo, University
of Alabama at Birmingham, Birmingham, AL) was used at 1:5000
dilution followed by an HRP-labeled goat anti-rabbit IgG Ab
(Jackson ImmunoResearch Lab. West Grove, PA) at 1:300,000
dilution. For a loading control, the enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) protein was used as described
previously [10,14].
Generation of cytolytic T lymphocytes (CTL) and
cytotoxicity tests
H-2K
b-restricted VSV-Np52–59 epitope specific CTLs were
generated by the following protocols: CMT.64, CMT.TAP1,
CMT.TAP/K
b, CMT.TAP1,2/K
b or 39.5/K
b cells were infected
respectively with VV-VSV-Np, VV-VSV-Np52–59 or VV-ss-VSV-
Np52–59 at 1:20 multiplicity of infection (m.o.i) for 12–16 hours,
and the viral infected cells were subjected to 10,000 rads c-
irradiation. After extensive washing, 1610
7 cells were injected i.p
into a C57BL/6 mouse for immunization. Immunized splenocytes
were obtained 7 to 8 days later and used as CTLs in a standard 4-h
51Cr-release assay described previously [10]. In some cases, the
CTLs were generated by direct immunization of a mouse with
1610
7 plaque formation units (p.f.u) VV-VSV-Np52–59 virus with
or without c-irradiation (Fig. 3D). For tumor-antigen CTLs,
1610
6 cells/mouse c-irradiated CMT.64 or CMT.TAP1,2/K
b
cells were injected i.p. into C57BL/6 mice. Procedures and a
standard 4 h
51Cr-release assay were described previously [10].
The
51Cr-labeled targets are described in each figure legend. For
each antigen, two or three experiments were performed and the
results represented the mean value (mean6SEM) from two or
three experiments.
Detection of frequencies of VSV-Np52–59-specific T cells
by a tetramer
Tetramer assays were described previously [25]. Splenocytes
from the immunized mice as described above were stimulated in
vitro with VSV-Np52–59 peptides for 5 days. After stimulation, the
splenocytes were divided into two aliquots; one was used as CTLs
in cytotoxicity tests (Fig. 3A and B) and the other was used to
measure the frequency of VSV-Np52–59-specific CD8
+ T cells
using double staining [after use of purified anti-mouse CD16/32
antibody (clone 93) to block Fc receptor for 10 min, Biolegend,
San Diego, CA ] with an FITC-conjugated anti-mouse CD8a
antibody, clone 53–6.7 (Biolegend) and an H-2K
b/VSV-Np52–59
tetramer conjugated to R-phycoerythrin (NIH, MHC Tetramer
Core Facility, Atlanta, GA) for 1 hour. After staining, the cells
were washed extensively with PBS and used for FACS assay. The
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debris. The percentage of tetramer positive cells in the splenocytes
and in the CD8
+ cells was calculated as follow: 1) (number of
tetramer positive events from each sample - number of non-
specific tetramer events from naı ¨ve splenocytes)/total accumulated
events in each sample; 2) (number of tetramer positive events from
each sample - number of non-specific tetramer events from naı ¨ve
splenocytes)/CD8
+ events in each sample. Total accumulated
events were 1610
4 events for all samples. The mean value
(mean6SEM) of the results from two experiments is shown.
Tumor challenge experiments
C57BL/6 mice were immunized i.p. with 1610
7 c-irradiated
CMT.TAP1,2/K
b, CMT.64/ppp (experimental control) cells, or
PBS (negative control). After 20 days, mice were challenged i.p.
with 2.5610
5 cells CMT.TAP1,2/K
b cells and the time of
morbidity was recorded. Each group contained 10 mice. Statistics
for mouse survival were performed using the Kaplan–Meier log
rank survival test and considered different if p,0.05.
Preparation of BM-DCs
BM-DCs were cultured as described previously [43]. BM-DCs
were generated from 6 to 8 week old C57BL6 (H-2
b) and BALB/c
(H-2
d) female mice. On day 6 of in vitro culture, immature BM-
DCs were exposed for 6 hours with c-irradiated tumor cells (1:1
ratio) that were infected with 1:10 m.o.i VV-VSV-Np52–59
overnight and were subsequently subject to maturation with
LPS. Mature BM-DCs were used either for T cell generation or as
targets for an in vitro cytotoxicity assay. For T cell generation, a
naı ¨ve mouse was inoculated i.p. with 3610
5 DCs for 7 days, and
splenocytes from the immunized mice were cultured in vitro for 4–5
days supplied with VSV-Np52–59 peptide and used as effectors.
DCs used as targets were labeled with
51Cr (as described above).
The mean value (mean6SEM) of the results from two experiments
is shown.
In vivo cytotoxicity assay
A C57BL/6 mouse was injected with 3610
5 antigen-loaded
BM-DCs from a BALB/c mouse for immunization (see above for
antigen-loading) and after 7 days the mouse was used for in vivo
cytotoxicity assay.
RBC-lysed, single-cell splenocytes from naı ¨ve C57BL/6 mice
werepulsed at1610
7 cells/mlwithorwithout20 mMVSV-Np52–59
peptide in DMEM containing 10% FBS for 30 min at 37uC.
Afterwards, the cells were washed with PBS twice and then labeled
with different concentrations of CFSE [0.5 mM for the cells without
peptide-loading (lo),or 5 mM for the cells pulsed with peptide (hi)] at
2610
7 cells/ml in PBS for 10 min. CFSE labeling was stopped by
addition of three-times volume of PBS containing 2% FBS for
1 min. After washing and re-suspension, 1610
7 cells of each
population were mixed at a concentration of 4610
7cells/ml and
0.5ml was injected i.v. into immunized and non-immunized
syngeneic mice. Five hours later, the mice were sacrificed, and
the spleens were harvested. Single-cell suspensions of splenocytes
were prepared and analyzed by FACS. Percent specific lysis of
fluorescent splenocytes in each mouse was calculated as follows:
[12(Ximmunized mouse/Xnaı ¨ve mouse)]6100%, where X=hi/lo. Two
experiments were performed.
Determination of uptake of MHC-I from tumor cells by
dendritic cells
Uptake of MHC-I from tumor cells by DCs was detected by
multi-channel fluorescence microscopy and FACS assay using a
GFP-tagged K
b system. CMT.64 and CMT.TAP1,2/K
b cells
were transiently transfected with a GFP-tagged K
b vector
overnight and were then c-irradiated (10000 rads). The cells were
then frozen at 220uC for one hour and incubated immediately
with BM-DCs (DCs were cultured on a cover-slip) at a 2:1 ratio of
tumor cells to DCs. After a 6-hour incubation, DCs were subjected
to maturation by adding LPS into the DC culture overnight. The
DCs were then pre-incubated with an antibody against CD16/32
(Biolegend) for 10 min to block Fc receptor and labeled with Alexa
Fluor 647 anti-mouse CD11c antibody. Uptake of GFP-tagged-K
b
by DCs was visualized using a Zeiss AxioObserver Z1 widefield
microscope. For FACS assay, DCs were labeled with PE-
conjugated anti-mouse CD11c antibody (Biolegend). CD11c
positive cells were gated as a DC population for detection of
uptake of GFP-tagged K
b. Note: transient, but not stable,
transfection of tumor cells with the GFP-tagged K
b vector for
our experiments was due to the impossibility of generating a stable
transfectant from CMT.TAP1,2/K
b cells because this cell line
already contains a neomycin marker from the TAP1-vector
(pcDNA3.1/His vector contains a neomycin marker).
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